Ionis Pharmaceuticals, Inc.
Price Action
Technical Summary
CONSOLIDATINGIonis Pharmaceuticals, Inc. is in a consolidation phase, trading with mixed signals as moving averages converge. Relative strength is moderate (RS Rating: 59), indicating performance broadly in line with the market. Earnings growth of 40% provides fundamental context to the price action. Volume support will be critical for the stock to resolve this consolidation to the upside.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $76.53 | +8.69% | ABOVE |
| 50 SMA | $75.62 | +9.99% | ABOVE |
| 100 SMA | $76.08 | +9.33% | ABOVE |
| 150 SMA | $77.67 | +7.10% | ABOVE |
| 200 SMA | $75.86 | +9.65% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is IONS in an uptrend right now?
IONS has a trend score of 2/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 2 of 4 trend criteria are met.
Is IONS overbought or oversold?
IONS's RSI (14) is 68. The stock is in neutral territory, neither overbought nor oversold.
Is IONS outperforming the market?
IONS has a Relative Strength (RS) Rating of 59 out of 99. IONS is performing about average compared to the market.
Where is IONS in its 52-week range?
IONS is trading at $83.18, which is 96% of its 52-week high ($86.74) and 92% above its 52-week low ($40.03).
How volatile is IONS?
IONS has a Beta of 0.34 and 52-week volatility of 46%. It's less volatile than the S&P 500 - generally more stable.